Technology News and Research

RSS

Zelos Therapeutics commences dosing in clinical study of ZT-034 nasal spray for osteoporosis

Zelos Therapeutics, Inc. has initiated dosing in a seven day clinical study of a nasal spray formulation of ZT-034 (teriparatide) that is being developed in collaboration with development partner Aegis Therapeutics, LLC. Nasal spray ZT-034 is being developed as an alternative to Eli Lilly and Company’s Forteo (teriparatide [rDNA origin]) which generated approximately $800M in annual sales in 2009 for the treatment of osteoporosis and is administered by daily injection.

28 Jan 2010

Innovative cardiac scanner allows early detection of heart conditions

The portable magnetometer is being developed at the University of Leeds, with funding from the Engineering and Physical Sciences Research Council (EPSRC) playing a key role.

28 Jan 2010

Ligand Pharmaceuticals acquires Metabasis Therapeutics

Ligand Pharmaceuticals Incorporated announced that it has completed the acquisition of Metabasis Therapeutics, Inc. (NASDAQ:MBRX), following approval of the transaction by Metabasis stockholders yesterday. As a result, Ligand gains a fully funded partnership with Roche, additional pipeline assets and drug discovery technologies and resources. The transaction was first announced on October 27, 2009.

28 Jan 2010

Oculus Innovative Sciences introduces Microcyn Solution for treatment of post-surgical wounds

Oculus Innovative Sciences, Inc., a commercial medical technology company that designs, produces and markets safe and effective tissue care products based upon the Microcyn® Technology platform, today unveiled Microcyn Solution with preservatives, at the New York Podiatric Clinical Conference & Exhibition being held in downtown Manhattan, January 29-31.

28 Jan 2010

EnteroMedics to submit an IDE application for next-generation Maestro RC System

EnteroMedics Inc., the developer of medical devices using neuroblocking technology to treat obesity and other gastrointestinal disorders, announced today that, following a recent meeting with the U.S. Food and Drug Administration (FDA) to discuss the Company’s EMPOWER™ study results and the regulatory process, the Company intends to submit an Investigational Device Exemption (IDE) application for a clinical trial to support a possible Premarket Approval (PMA) application for the next-generation Maestro® RC System in the treatment of morbid obesity.

28 Jan 2010

Kensey Nash announces financial results for second quarter of fiscal year 2010

Kensey Nash Corporation, a leading medical technology company that provides innovative solutions and technologies for a wide range of medical procedures, today reported the results for its three and six months ended December 31, 2009.

28 Jan 2010

Life Technologies reports fourth-quarter and fiscal year results ended December 31, 2009

Life Technologies Corporation today announced results for its fourth quarter and full year ending December 31, 2009. Non-GAAP revenue for the fourth quarter was $874 million, resulting in full year non-GAAP revenues of $3.30 billion, an increase of 5 percent over the $3.14 billion reported for 2008, as if Invitrogen and Applied Biosystems had been combined.

From Danaher 28 Jan 2010

Cenduit announces strategic business alliance with invivodata

Cenduit, LLC, and invivodata, inc., today announce a strategic business alliance to further improve clinical trial efficiencies by adding the scientific and operational benefits of invivodata’s electronic Patient Reported Outcomes (ePRO) solutions to the proven efficiencies of Cenduit‘s Interactive Response Technology solution (IRT).

28 Jan 2010

NBTY announces record results for fiscal first quarter

NBTY, Inc. (NYSE: NTY), a leading global manufacturer and marketer of nutritional supplements, today announced record results for the fiscal first quarter ended December 31, 2009.

28 Jan 2010

ZOLL Medical, HealthTrust Purchasing Group enter into purchasing agreement

ZOLL Medical Corporation, a manufacturer of medical devices and related software solutions, announced today that HealthTrust Purchasing Group, LP (HealthTrust), a leading healthcare group purchasing organization (GPO), has entered into a purchasing agreement with ZOLL for its therapeutic temperature management equipment.

28 Jan 2010

Encision reports financial results for third-quarter of fiscal year 2010

Encision Inc., a medical device company owning patented surgical technology that is emerging as a standard of care in minimally-invasive surgery, reported its financial results for its third quarter of fiscal year 2010.

28 Jan 2010

Christiana Care Health System introduces COPE technology for common diagnoses

Christiana Care Health System is taking a giant leap forward toward a comprehensive Electronic Health Record with the launch of Computerized Provider Order Entry (CPOE), technology that makes it easier, more efficient and safer for doctors to order tests and medications.

28 Jan 2010

Sexuality publishing portfolio gains key journal

Starting in 2010, Springer will publish the journal Sexuality Research and Social Policy. All aspects of sexual behavior are covered in the journal, including a unique focus on lesbian, gay, bisexual, and transgender populations. The journal was previously published by the University of California Press.

28 Jan 2010

Transcend Services announces unaudited financial results for fourth-quarter of 2009

TRANSCEND SERVICES, INC., a leading provider of medical transcription services to the U.S. healthcare market, today announced its unaudited financial results for the fourth quarter and year ended December 31, 2009.

28 Jan 2010

New research raises concerns over cost-benefits and NHS treatments

New research by health economists at the University of York has raised concerns over any move to broaden the range of costs and economic benefits considered in the analysis of new NHS treatments.

28 Jan 2010

New insight into reprogramming of cells

A discovery by Babraham scientists brings new insight into how cells are reprogrammed and a greater understanding of how the environment, or factors like nutritional signals, can interact with our genes to affect health. As an embryo develops, cells acquire a particular fate, for example becoming a nerve or skin cell. The findings, reported online in the journal Nature, pinpoint a protein called AID as being important for complete cellular reprogramming in mammals.

28 Jan 2010

Study shows ActiveHealth's VBID programs increase adherence to medications

ActiveHealth Management (ActiveHealth®), a subsidiary of Aetna, today announced the publication of a paper in the February issue of Health Affairs. The paper demonstrates that properly structured value-based insurance design (VBID) programs can be effective at increasing adherence to drug regimens for specific chronic medical conditions without increasing overall costs.

28 Jan 2010

Onset Therapeutics expands its sales force to create nationwide presence

Onset Therapeutics LLC, a specialty pharmaceutical company focused in dermatology, today announced that the Company’s recent growth and future opportunities have facilitated an expansion of its field sales organization to cover more than twenty-five additional major metropolitan areas.

28 Jan 2010

JST chooses Scopus Custom Data to conduct citation linkage analysis

Elsevier announced today that Scopus Custom Data, the underlying source of Scopus.com, the world's largest abstract and citation database, was chosen by Japan Science and Technology (JST) to conduct citation linkage analysis between scientific articles and patents.

28 Jan 2010

Alli boosts weight loss and reduces excess visceral fat

New studies show that overweight and obese people using alli® (orlistat 60 mg) with a reduced calorie, lower-fat diet can significantly reduce weight, visceral fat, and waist circumference and therefore may reduce their risk of type 2 diabetes, hypertension, heart disease and stroke.

28 Jan 2010